Posted by Michael Wonder on 28 Aug 2024
Kye Pharmaceuticals announces approval in Canada for ACCRUFeR (ferric maltol) for the treatment of iron deficiency anaemia in adult patients
27 August 2024 - Kye Pharmaceuticals today announced that ACCRUFeR (ferric maltol) has received market authorisation as a prescription medicine in Canada for adults with iron deficiency anaemia who are unresponsive or intolerant to other oral iron preparations.
Accrufer is currently the only prescription-only oral treatment option indicated for ID/IDA in Canada.
